scholarly journals Next-generation sequencing for cancer drug development: the present and visions for the future

2014 ◽  
Vol 11 (2) ◽  
pp. 139-142
Author(s):  
Scott M Kahn
2014 ◽  
Vol 11 (4) ◽  
pp. 699-707 ◽  
Author(s):  
Katja Lohmann ◽  
Christine Klein

2015 ◽  
Vol 76 ◽  
pp. 165
Author(s):  
Hayley Hogan ◽  
Rhys Cransberg ◽  
Megan Jordan ◽  
Damian Goodridge ◽  
David Sayer

Food Control ◽  
2019 ◽  
Vol 101 ◽  
pp. 134-143 ◽  
Author(s):  
Edward Haynes ◽  
Elisa Jimenez ◽  
Miguel Angel Pardo ◽  
Sarah J. Helyar

2011 ◽  
Vol 8 (3) ◽  
pp. 331-345 ◽  
Author(s):  
Rebecca Y Kim ◽  
Hua Xu ◽  
Samuel Myllykangas ◽  
Hanlee Ji

Author(s):  
Michael Offin ◽  
Dazhi Liu ◽  
Alexander Drilon

Therapies designed to target cancers that harbor specific molecular signatures have reshaped the landscape of oncologic drug development, and advances in next generation sequencing have led to an increase in the identification of these alterations across tumor types. Tumor-agnostic trial designs, such as the “basket trial,” have been developed as an approach to study the efficacy of these treatments and increase patient access, especially for patients whose tumors carry these alterations infrequently. We review key aspects of these genomically enriched trial strategies and their impact on drug development and approval.


Sign in / Sign up

Export Citation Format

Share Document